GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Book Value per Share

CNSP (CNS Pharmaceuticals) Book Value per Share : $5.01 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals Book Value per Share?

CNS Pharmaceuticals's book value per share for the quarter that ended in Sep. 2024 was $5.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

CNS Pharmaceuticals's current price is $2.30. Its book value per share for the quarter that ended in Sep. 2024 was $5.01. Hence, today's PB Ratio of CNS Pharmaceuticals is 0.46.

During the past 7 years, the highest P/B Ratio of CNS Pharmaceuticals was 32.51. The lowest was 0.00. And the median was 0.00.


CNS Pharmaceuticals Book Value per Share Historical Data

The historical data trend for CNS Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNS Pharmaceuticals Book Value per Share Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial - - - 8,133.00 -2,216.00

CNS Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -870.50 -2,216.00 -1,107.75 -148.07 5.01

Competitive Comparison of CNS Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, CNS Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNS Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's PB Ratio falls into.



CNS Pharmaceuticals Book Value per Share Calculation

CNS Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-4.43-0.00)/0.00
=-2,216.00

CNS Pharmaceuticals's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.35-0.00)/0.67
=5.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


CNS Pharmaceuticals  (NAS:CNSP) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


CNS Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CNS Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Executives
Christopher Downs officer: Chief Financial Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco director, officer: Chief Executive Officer PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes director 13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027